US-approved Neulasta

BIOLOGICAL2 trials

Sponsors

Pfizer

Conditions

Healthy VolunteersNeutropenia

Phase 1

A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants

CompletedNCT02629289

PfizerNeutropenia

Start: 2015-08-31End: 2016-06-30Updated: 2016-07-15

A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers

CompletedNCT03273842

PfizerHealthy Volunteers

Start: 2017-10-27End: 2018-07-25Updated: 2018-09-05

Related Papers

Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer.

2021-10-07

PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta®): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers

Advances in Therapy2020-06-108 citations